Mobile

A multi-centre randomized double blind 52-week study to assess the safety of QVA149 compared to QAB149 in patients with COPD who have moderate to severe airflow limitation

Mise à jour : Il y a 4 ans
Référence : EUCTR2012-001998-93

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

To evaluate the safety and tolerability of QVA149 27.5/12.5 μg b.i.d. and QVA149 27.5/25 μg b.i.d. in terms of adverse event reporting rate in patients with Chronic Obstructive Pulmonary Disease (COPD) with moderate to severe airflow limitation during 52 weeks of treatment.

Critère d'inclusion

  • Chronic Obstructive Pulmonary Disease (COPD)

Liens